92569-02-3

Basic information

• Product Name: Propanamide,N-[[(5S,6R,7R,9R,14aS,15R)-7-cyano-1,5,6,7,9,10,13,14,14a,15-decahydro-5-hydroxy-2,11-dimethoxy-3,12,16-trimethyl-1,4,10,13-tetraoxo-6,15-imino-4H-isoquino[3,2-b][3]benzazocin-9-yl]methyl]-2-oxo-
• Synonyms: Propanamide,N-[(7-cyano-1,5,6,7,9,10,13,14,14a,15-decahydro-5-hydroxy-2,11-dimethoxy-3,12,16-trimethyl-1,4,10,13-tetraoxo-6,15-imino-4H-isoquino[3,2-b][3]benzazocin-9-yl)methyl]-2-oxo-,[5S-(5a,6a,7a,9b,14aa,15a)]-; 6,15-Imino-4H-isoquino[3,2-b][3]benzazocine, propanamide deriv.;(-)-Saframycin G; Saframycin G
• CAS NO: 92569-02-3
• Molecular Formula: C29H30 N4 O9
• Molecular Weight: 578.5699
• Mol File: 92569-02-3.mol

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.48g/cm³
• Refractive Index: 1.645
• CAS DataBase Reference: Propanamide,N-[[(5S,6R,7R,9R,14aS,15R)-7-cyano-1,5,6,7,9,10,13,14,14a,15-decahydro-5-hydroxy-2,11-dimethoxy-3,12,16-trimethyl-1,4,10,13-tetraoxo-6,15-imino-4H-isoquino[3,2-b][3]benzazocin-9-yl]methyl]-2-oxo-(CAS DataBase Reference)
• NIST Chemistry Reference: Propanamide,N-[[(5S,6R,7R,9R,14aS,15R)-7-cyano-1,5,6,7,9,10,13,14,14a,15-decahydro-5-hydroxy-2,11-dimethoxy-3,12,16-trimethyl-1,4,10,13-tetraoxo-6,15-imino-4H-isoquino[3,2-b][3]benzazocin-9-yl]methyl]-2-oxo-(92569-02-3)
• EPA Substance Registry System: Propanamide,N-[[(5S,6R,7R,9R,14aS,15R)-7-cyano-1,5,6,7,9,10,13,14,14a,15-decahydro-5-hydroxy-2,11-dimethoxy-3,12,16-trimethyl-1,4,10,13-tetraoxo-6,15-imino-4H-isoquino[3,2-b][3]benzazocin-9-yl]methyl]-2-oxo-(92569-02-3)

Safety Data

• Hazardous Substances Data: 92569-02-3(Hazardous Substances Data)

Usage

InChI:InChI=1/C29H30N4O9/c1-10-22(35)13-7-14-20-18-19(23(36)11(2)28(42-6)26(18)39)24(37)21(32(20)4)15(8-30)33(14)16(9-31-29(40)12(3)34)17(13)25(38)27(10)41-5/h14-16,20-21,24,37H,7,9H2,1-6H3,(H,31,40)/t14-,15?,16-,20?,21?,24-/m0/s1

Upstream product

• 66082-27-7 (-)-saframycin A 
• 64-19-7 acetic acid 
• 66082-27-7 Saframycin A 
• 160952-79-4 C₂₉H₃₄N₄O₉ 
• 160952-80-7 N-<(7-cyano-6,7,9,10,13,14,14a,15-octahydro-1,4,5-trihydroxy-2,11-dimethoxy-3,12,16-trimethyl-10,13-dioxo-5β,6α,7α,9α,14aα,15α-6,15-imino-5H-isoquino<3,2-b><3>benzazocin-9-yl)methyl>-2-oxopropanamide 

Relevant articles and documents

Synthesis of saframycins. X. Transformation of (-)-saframycin A to (-)-saframycin Mx type compound with the structure proposed for saframycin E.

Treatment of (-)-saframycin A (1a) with selenium oxide in acetic acid afforded (-)-saframycin G (1g), and a catalytic reduction and regioselective oxidation sequence afforded the saframycin Mx type compound (3). We applied this methodology to the transformation of (±)-5-hydroxysaframycin B (11) to the hydroquinone (1e). Acetylation of 1e with acetic anhydride in pyridine gave the triacetate (13), which is identical with the triacetyl derivative of natural saframycin E.

Synthesis of saframycins. VI. The useful transformation of (-)-saframycin A to (-)-saframycin Mx type compound

A transformation of (-)-saramycin A 3 to the saframycin Mx type compound 15 is described. Treating (-)-saframycin A 3 with selenium oxide in acetic acid afforded (-)-saframycin G 8, followed by catalytic reduction and regioselective oxidation to provide the hydroquinone 15.